Press Release: Breaking New Ground in Breast Cancer Diagnostics: ThermoBreast Welcomes the First Patients in the Pioneering Clinical Trial

ThermoBreast is excited to share the news of our anticipated press release, marking the beginning of patient recruitment in our innovative diagnostic clinical trial. The project has launched its pioneering trial and has already welcomed more than 400 participants.

Following a recent successful feasibility trial with 100 participants at Klinik Sankt Elisabeth in Heidelberg, Germany, ThermoBreast is now expanding to 11 other clinical centres around the world. In December 2023, the first patient was recruited within the main trial at University Hospital Heidelberg, which is also leading the clinical trial. To date, several devices have been successfully deployed at partner clinical sites at University Hospital Heidelberg and Klinik Sankt Elisabeth (Heidelberg, Germany) and Assuta Medical Centers in Haifa and Tel Aviv (Israel). Recruiting the first patients for this groundbreaking clinical trial marks a significant milestone for ThermoBreast in its goal to develop safe, pain-free, and accurate breast cancer diagnostics applicable to women of any age and breast density. Since December 2023, more than 400 patients have undergone the ThermoBreast screening procedure in the aforementioned clinical sites, paving the way for the ultimate goal of recruiting 28,000 patients for the study. Several other clinics and hospitals in France (Institute Gustav Roussy), Ireland (University College Cork), Italy (Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino), Slovenia (Univerzitetni Klinicni Center Maribor), Lithuania (Hospital of Lithuanian University of Health Sciences Kaunas Clinics), and the US (MD Anderson Cancer Center) are also preparing to begin patient recruitment for the ThermoBreast trial. As a consortium partner, Cancer Patients Europe is committed to enhancing a credible and reliable alternative to mammography for breast cancer screening. ThermoBreast is well set to provide this alternative. This is why CPE is actively exploring the necessary level of explainability for the ThermoBreast solution to ensure a patient-centred approach in the trial process.

To download the full press release, please visit this page.

You can also find the live count of performed ThermoBreast screenings on our Home page.

To learn more about the study and how to participate, please visit this page.